Market Overview

UPDATE: Bank of America Merrill Lynch Reiterates Neutral Rating, Lowers PO on Boston Scientific

Share:
Related BSX
Needham Calls Boston Scientific's Results Just 'Decent'
Boston Scientific Posts In-Line Q1 Earnings, Issues Weak Outlook
Vanguard Adds to Four of Its Largest Stakes (GuruFocus)

In a report published Friday, Bank of America Merrill Lynch reiterated its Neutral rating on Boston Scientific (NYSE: BSX), but lowered its price objective from $8.50 to $6.30.

BofA Merrill Lynch noted, “In order to be more bullish on BSX, we need more conviction that ASP declines in BSX's core drug-eluting stent market will moderate and the Promus Element stent can be successful in the U.S. in order to allow for operating leverage, and we need more conviction that BSX can grow. If we became more convinced that operating leverage will materialize, it would make it much easier to call BSX cheap and to argue that a positive risk reward exists while we wait for management's plan to play out.”

Boston Scientific closed on Thursday at $5.66.

Latest Ratings for BSX

DateFirmActionFromTo
Apr 2015BarclaysMaintainsOverweight
Apr 2015Leerink SwannMaintainsOutperform
Apr 2015RBC CapitalMaintainsOutperform

View More Analyst Ratings for BSX
View the Latest Analyst Ratings

Posted-In: Bank of America Merrill LynchAnalyst Color Price Target Analyst Ratings

 

Related Articles (BSX)

Around the Web, We're Loving...